Edwards Lifesciences (EW) Cash from Financing Activities (2009 - 2026)

Edwards Lifesciences has reported Cash from Financing Activities for 18 years, with the latest figure at -$300000.0 in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 100.57% year-over-year to -$300000.0 in Q2 2026; TTM through Jun 2026 was -$1.2 billion, a 4.3% decrease from a year earlier, with the FY2025 full-year figure at -$956.8 million, up 2.67% from the prior year.
• Cash from Financing Activities was -$300000.0 for Q2 2026 at Edwards Lifesciences, up from -$451.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $61.7 million in Q1 2024, with the low at -$976.7 million in Q3 2024.
• Average Cash from Financing Activities over 5 years is -$260.4 million, with a median of -$175.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 1252.26% in 2022, then jumped 154.55% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$838.4 million in 2022, then jumped by 50.72% to -$413.2 million in 2023, then soared by 106.92% to $28.6 million in 2024, then sank by 139.86% to -$11.4 million in 2025, then surged by 97.37% to -$300000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$300000.0 (Q2 2026), -$451.2 million (Q1 2026), and -$11.4 million (Q4 2025), per Business Quant data.